Ras protein over-expression has been observed in human breast cancers although the signi®cance of Ras overexpression in the etiology of breast cancer is unknown and its contribution to breast cancer prognosis is still debated. In this study, the over-expression of both wildtype Harvey and Kirsten Ras proteins as contributors to rat mammary carcinogenesis were examined using a transgenic rat model. Three rat transgenic lines (designated HrHr transgenics) carrying three to six copies of wild-type rat Harvey ras driven by the wildtype rat Harvey ras promoter were produced. In addition, transgenic lines carrying either three or seven copies of the Kirsten ras gene under the same promoter (HrKr) were produced. No pathological changes in the mammary gland were observed in any of the HrHr or HrKr transgenic rat line heterozygotes. Two of the Ras transgenic lines, HrHr (R8) and HrKr (4334), had a signi®cant reduction in NMU-induced rat mammary cancer when compared to their non-transgenic littermates. All ®ve Ras transgenic lines developed fewer carcinomas than their non-transgenic littermates following NMU exposure. The percentage of NMU-induced G35 to A35 activating mutations in the endogenous Harvey ras gene in mammary carcinomas from the HrHr, HrKr transgenic rats and their non-transgenic littermates was similar (*50%). In contrast, less than 1% of the NMU-induced carcinomas in these Ras transgenic rats had an activating ras mutation in their transgenes. These ®ndings highlight the potential of Ras to function as a modi®er gene in repressing mammary carcinogenesis.
Introduction
The molecular etiology of most breast cancers is poorly understood. There is evidence linking mutational inactivation of suppressor genes, such as BRCA1 and BRCA2, to breast cancer susceptibility (reviewed in Nathanson et al., 2001) . In contrast, mutational activation of oncogenes is rarely found in breast cancer, whereas many breast cancers over-express protooncogenes, such as ras and neu (reviewed in Clark and Der, 1995) . Clinical correlative studies have reported the association of Ras protein over-expression and disease progression (Hand et al., 1984; Lundy et al., 1986; Ohuchi et al., 1986; Clair et al., 1987; Querzoli et al., 1988; Watson et al., 1991; Shackney et al., 1998; Schondorf et al., 1999; . However, these studies have produced con¯ict-ing data regarding Ras over-expression and prognosis. Even less is known about the role of Ras overexpression in breast cancer etiology.
Studies of Ras over-expression in experimental models suggest a role for ras in cellular transformation both in vitro (Chakraborty et al., 1991) and in vivo (Thompson et al., 1997) . In contrast, over-expression of Ras in cultured cells has also been shown to revert the transforming activity of ras (Spandidos and Wilkie, 1988) . Interestingly, in Rat 1 cells in which one allele of the endogenous wild-type Harvey ras was replaced with an activated mutant form of ras, the ratio of wild-type ras and mutationally activated ras was shown to be an important factor in cellular transformation (Finney and Bishop, 1993) . Recently Zhang et al. (2001) reported that mice with a single K-ras gene were more susceptible to chemically induced lung cancer, suggesting that wild-type K-ras was acting as a suppressor gene in this context.
There are at least two studies in which the overexpression of wild-type Harvey ras has been shown to be involved in mammary cancer etiology using in vivo model systems. We have shown that when wild-type Harvey ras is over-expressed by retroviral infection in the in situ mammary parenchyma, rat mammary carcinomas develop (Thompson et al., 1997) . In contrast, transgenic rats expressing the wild-type human Harvey ras gene driven by a human Harvey ras truncated promoter element did not develop carcinomas in the mammary gland (Asamoto et al., 2000; Tsuda et al., 2001) . Transgenic Harvey ras expression in these rats did however increase the yield of mammary carcinomas following the administration of the mammary carcinogen N-nitroso-N-methylurea (NMU). In both these examples, Harvey ras was expressed using exogenous promoters that may have superimposed aberrant ras regulation upon ras overexpression. The potential of abnormal ras regulation is highest in the ®rst example, in which Harvey ras expression was regulated by the Moloney murine leukemia virus long terminal repeat (MMLV ± LTR) of the retroviral vector. In the second example, ras expression was controlled by a human ras promoter that was both truncated at the 5' upstream region and, in addition, contained an intron mutation known to increase Harvey ras expression (Cohen and Levinson, 1988) . Interestingly, when Kirsten ras was expressed in the mammary gland using the same retroviral model and vector, a diminished carcinogenic response was observed demonstrating a ras isoform speci®city for mammary carcinogenesis (Thompson et al., 1997) .
While these studies clearly demonstrate the potential of the aberrant expression of ras to participate in the multistage process of breast carcinogenesis, it is unclear what role ras over-expression would play if driven by its native promoter. Here we address this question by studying the eects of Harvey ras or Kirsten ras overexpression from the Harvey ras native rat promoter. None of the multiple transgenic lines carrying either rat Harvey or Kirsten ras showed any mammary pathology; however, when treated with the mammary carcinogen NMU, transgenic rats over-expressing Harvey or Kirsten ras driven by the Harvey ras native promoter showed an inhibition to NMU-induced mammary carcinogenesis.
Results

HrHr and HrKr transgenic rat production and characterization
Following the construction of the HrHr transgene (Figure 1 ), three transgenic lines were produced in which the transgene segregated in a Mendelian fashion. All HrHr transgenic lines were maintained as heterozygotes for these studies. Heterozygotes of these transgenic lines carried an estimated three to six copies of the HrHr transgene (Figure 2a ) in addition to the endogenous rat Harvey ras genes. No pathological eects were observed in any of the HrHr transgenic rat lines as measured by animal hardiness, spontaneous tumor incidence, or lifespan reduction (data not shown).
One HrHr transgenic line, designated R8, was characterized extensively for these studies. R8 transgenic rats were found to carry approximately ®ve copies of the HrHr transgene as heterozygotes ( Figure  2a ) with transgene expression observed in all tissues examined including the liver, kidney, colon, skeletal muscle, and mammary gland (data not shown). Results from¯uorescence in situ hybridization (FISH) analysis con®rmed the presence of multiple copies of the HrHr transgene located on chromosome 15 at position p12 in the R8 transgenic line (data not shown).
The Harvey ras coding region in the HrHr transgene was replaced with the rat Kirsten ras 2B Figure 2b ) at a single chromosomal location at 3q22 (data not shown). The 4334 transgenic line was found to carry three copies of the HrKr transgene (Figure 2b ). Similar to that observed in the HrHr transgenic lines, no pathological eects were observed in either of the HrKr transgenic rat lines and transgene expression was observed in all tissues examined (data not shown).
NMU-induced mammary carcinogenesis studies in HrHr transgenic rat lines
Exposure of female R8 HrHr transgenics and nontransgenic littermates to 50 mg/kg NMU at 42 to 50 days of age led to the development of mammary carcinomas starting at 4 weeks after NMU exposure. Two independent NMU-induced mammary carcinogenesis studies were performed in the R8 HrHr transgenic line with comparable results. All mammary tumors that developed in these studies following NMU administration were diagnosed as carcinomas by histopathological analysis. An average of 1.2 mammary carcinomas per rat in R8 HrHr transgenics and 2.7 mammary carcinomas per rat in non-transgenic littermates were observed 18 weeks after NMU exposure, which was signi®cantly dierent (P50.0005; Table 1 and Figure 3a ).
As observed with the R8 HrHr transgenic rats exposed to NMU, the yield of mammary carcinomas in the 3130 and 3157 HrHr transgenic lines following NMU exposure was less than the number observed in non-transgenic littermates (Figures 3b, c) . While a trend toward reduced tumor development in these HrHr transgenic rats was found, it did not reach the threshold of signi®cance for either the 3130 or 3157 line when analysed individually (Table 1 ). This may have resulted from lack of power due to the smaller group sizes; however, when the data is pooled for the 3130 and 3157 lines, the same trend is observed with a P-value=0.04. No mammary carcinomas developed in any of the HrHr transgenic rats or non-transgenic littermates not exposed to NMU (data not shown).
NMU-induced mammary carcinogenesis studies with the HrKr transgenic rat lines
Exposure of female 4321 and 4334 HrKr transgenics and non-transgenic littermates to 50 mg/kg NMU at 42 to 50 days of age led to the development of mammary carcinomas starting at 5 and 6 weeks after NMU exposure, respectively (Figure 4a, b) . All mammary tumors that developed in these studies following NMU administration were diagnosed as carcinomas by histopathological analysis. An average of 3.1 mammary carcinomas per rat in 4321 HrKr transgenics and 3.5 mammary carcinomas per rat in non-transgenic littermates were observed 18 weeks after NMU exposure, which was not signi®cantly dierent (P=0.17; Table 1 ). In contrast to the 4321 HrKr line, 4334 HrKr transgenics rats exposed to NMU developed a signi®cantly lower number of mammary carcinomas with an average of 2.5 mammary carcinomas per rat compared to 4.5 mammary carcinomas per rat in nontransgenic littermates 18 weeks after NMU exposure (P=0.002; Table 1 ). As observed with the HrHr transgenic lines, no mammary carcinomas developed in the HrKr transgenic rats or non-transgenic littermates not exposed to NMU (data not shown). Figure 5 shows results from the designed diagnostic restriction fragment length polymorphism (RFLP) assay (Kumar and Dunn, 1989) used to determine the presence of G35 to A35 activating mutations in the endogenous Harvey ras gene and the HrHr transgene of NMU-induced mammary carcinomas in the R8 HrHr transgenic rats. The percentage of NMU-induced mammary tumors with mutations in the endogenous Harvey ras gene and the HrHr transgenes are shown in Table 2 . Approximately 56% of the mammary carcinomas from both the R8 HrHr transgenic line and their non-transgenic littermates had G35 to A35 activating mutations in the endogenous Harvey ras gene. In contrast, of 50 mammary carcinomas assayed, only a single NMU-induced mammary carcinoma from the R8 HrHr transgenic rat line was identi®ed with an activating mutation in the HrHr transgene (Table 2 ). In the HrKr transgenic lines 4321, which did not show the phenotype of reduced NMU-induced tumorigen- (Table 2) .
Analysis of G35 to A35 NMU-induced activating mutations in the endogenous-and transgenic-ras genes
Discussion
In order to model the role of wild-type ras overexpression in the mammary carcinogenesis process, while limiting potential confounding temporal and spatial eects on gene regulation, we produced several transgenic rat lines carrying wild-type Harvey ras or Kirsten ras driven by the rat Harvey ras promoter. We feel this approach minimizes aberrant regulation of Harvey ras gene expression; however, it should be stressed that the potential for abnormal gene regulation exists in all transgenic lines due to the in¯uence of the genomic integration site of the transgene. In all ®ve ras transgenic lines, which were followed for their lifespan, spontaneously developing mammary carcinoma frequency did not dier from that observed in their non-transgenic littermates. In addition, when these transgenic rat lines were exposed to NMU, mammary carcinogenesis was signi®cantly reduced in comparison to non-transgenic littermates in two of the lines. Our current observations can be compared to the results presented in two other studies. The ®rst study, performed in our laboratory, reported that when wild- type Harvey ras is directed to and over-expressed in the in situ mammary gland by infection with a retroviral vector, carcinomas arise after an extended latency (Thompson et al., 1997) . The second observation is that reported by Asamoto et al. (2000) and Tsuda et al. (2001) , who produced transgenic rats using a wild-type human Harvey ras construct driven by truncated and mutated ras gene regulatory elements. While this rat ras transgenic line did not develop mammary carcinomas over the course of the study without carcinogen exposure, these rats were highly sensitive to the development of mammary carcinomas following DMBA and NMU treatment when compared to control rats.
Several dierences exist between our current study and these previous studies. The Harvey ras transgenes in the current study were driven by extensive regulatory elements of the rat Harvey ras gene (Ariazi et al., 1995) . In contrast, in our retrovirus vector study (Thompson et al., 1997) , Harvey ras was driven by the MMLV ± LTR of the retroviral vector. In the Asamoto and Tsuda studies (Asamoto et al., 2000; Tsuda et al., 2001) , the transgenic rat line used a human Harvey ras transgene with a truncated human Harvey ras promoter. The human Harvey ras regulatory sequences used in the Asamoto and Tsuda studies dier extensively from the endogenous human Harvey ras gene. For example, the human Harvey ras sequence used for transgene construction contains a mutation in the last intron that results in abnormal expression of Harvey ras (Cohen and Levinson, 1988) . Thus, like in the case of the retroviral vector, expression from the human construct may give aberrant expression, which results in enhanced susceptibility to mammary carcinogenesis due to abnormal temporal regulation of Harvey ras expression or a higher level of Ras protein expression. In addition, the 5' promoter sequence used contains only a limited region adjacent to the ®rst ras exon. Since the human and rat 5' regulatory sequences dier, the use of human ras regulatory sequences expressed in the rat mammary gland may be abnormally regulated in comparison to that of the native rat Harvey ras gene. While the timing of ras gene expression in the context of rat mammary cells could result in these inter-study dierences, it is also possible that these dierent control elements could result in diering levels of Ras protein over-expression within the mammary cells. If this was the case, it is plausible that this could account, at least in part, for dierences between these studies.
The ®nding of decreased NMU-induced mammary carcinogenesis in both a HrHr and HrKr transgenic line supports the conclusion that this decrease in susceptibility was not simply due to a transgenic positional-insertion eect. Also, unlike our observation of the occurrence of Ras isoform speci®city for the induction of mammary cancer (Thompson et al., 1997) , no isoform speci®city was observed for the current endpoint of the inhibition of NMU-induced mammary carcinogenesis.
While ras activated by mutation has clearly been shown to drive transformation in many dierent cell types, it has also been shown to enhance anticarcinogenic activities. The latter includes ras stimulated dierentiation, senescence, and apoptosis. For example, the expression of oncogenic ras in PC-12 pheochromocytoma cells leads to the development of neurite outgrowths and the induction of a more dierentiated 1 2 3 4 5 6 7 8 9 10 11 12 Figure 5 Designed diagnostic RFLP assay for G35 to A35 mutations in the endogenous Harvey ras gene and the R8 HrHr transgenes. Lanes 1 and 12 have 50 bp and 100 bp DNA ladders, respectively; lane 2. Hph I digested PCR product with arrow (A) showing band resulting from presence of a G35 to A35 mutation in the endogenous rat Harvey ras gene; lane 3. Undigested PCR product from lane 2; lane 4. Hph I digested PCR product from carcinoma without a G35 to A35 mutation in the endogenous Harvey ras gene; lane 5. Undigested PCR product from lane 4; lane 6. BstN I digested PCR product from a mammary carcinoma without a mutation in the HrHr transgene; lanes 7 and 8 Undigested and Hph I digested PCR product following designed diagnostic RFLP ampli®cation of product from lane 6, respectively; lane 9. BstN I digested PCR ampli®cation product from a mammary tumor with a G35 to A35 mutation in the R8 HrHr transgene; lane 10. Undigested Hph I designed diagnostic RFLP ampli®cation of BstN I digested PCR product from lane 9; lane 11. Hph I digested PCR product from lane 10 with arrow (B) showing band resulting from the presence of a G35 to A35 mutation present in the HrHr transgene. Rationale for the restriction digests performed is explained in Materials and methods. The image of the ethidium bromide stained gel was reversed to aid in visualizing DNA bands phenotype (Bar-Sagi and Feramisco, 1985) . Dierentiation of 3T3-L1 cells to adipocytes can be induced by oncogenic ras expression (Benito et al., 1991) . Alternatively, ras may inhibit tumorigenesis by inducing senescence. For example, expression of oncogenic ras in primary human and rodent cells has been shown to induce growth arrest with the development of a senescent phenotype (Serrano et al., 1997) . Apoptosis may also be aected by ras expression with the induction of a p53-independent apoptotic response (Mayo et al., 1997) . Also, FAS-induced apoptosis in lymphoid lines requires a functional Ras signaling pathway (Gulbins et al., 1995) . While the abovereferenced studies focused on mutationally activated ras, other studies show that wild-type ras can also suppress the transforming ability of activated ras (Spandidos and Wilkie, 1988) . It remains unclear if these or other mechanisms resulting from Ras overexpression contribute to the reduction of NMU-induced mammary carcinomas found in this study.
The over-expression of wild-type rat Harvey ras or Kirsten ras in the transgenic mammary gland did not aect the process of activation or selection of the endogenous Harvey ras gene in NMU-induced rat mammary carcinogenesis. The percentage of NMUinduced mammary carcinomas with activating G35 to A35 transition mutations in the endogenous Harvey ras gene was the same in mammary carcinomas from both non-transgenic and transgenic rats (i.e., approximately 50%). Therefore, the endogenous Harvey ras gene was equally mutable or selectable in NMU-induced mammary carcinomas in Harvey and Kirsten ras transgenic rats and their non-transgenic littermates. In contrast to the high percentage of mutations observed in the endogenous rat Harvey ras gene, the percentage of activating mutations in the HrHr or HrKr transgenes was found to be much lower (i.e., in less than 1% of carcinomas assayed). Positional eects of the transgene integration site may aect the ability of the ras transgenes to be mutated by NMU exposure. However, this possibility is minimized in that three independent Ras transgenic lines had similar transgene activation frequencies but diered in their susceptibilities to NMU-induced mammary carcinogenesis (i.e., resistant R8 HrHr and 4334 HrKr lines; susceptible 4321 HrKr line). Alternatively, transgene structure may in¯uence mutability. For example, absence of the second, third, and fourth rat Harvey ras introns in the HrHr transgene may aect the production of NMU-induced mutations in the Harvey ras transgene by, as yet, unknown mechanisms. In contrast to the current study, 86.4 per cent of NMU-induced mammary carcinomas had activating mutations in the transduced human Harvey ras transgene, and no activating mutations were observed in the endogenous rat Harvey ras gene of these tumors in the Asamoto and Tsuda studies (Asamoto et al., 2000; Tsuda et al., 2001) . Understanding which factors are important in regulating dierential mutation frequencies between transgenes and the analogous endogenous gene may provide insight into the carcinogenesis process.
While the dierences between studies can be attributed to mutation rates in the endogenous ras genes and transgenes in these dierent rat strains, another possibility could be considered. Zarbl and colleagues (Cha et al., 1994) have suggested that the mutated Harvey ras found in many NMU-induced rat mammary carcinomas were selected from a pool of mammary cells with preexisting activating mutations in the Harvey ras gene. They further suggested that NMU exposure caused a selective alteration in the con®rma-tion of the Harvey ras promoter that was irreversible and that this altered promoter con®rmation leads to altered ras gene regulation resulting in an increased penetrance of the ras mutation (Jin et al., 1996) . It is thus possible that the promoter sequence used to control our transgene expression was not susceptible to this NMU induced conformation change of the Harvey ras promoter. In contrast, the transgene used with the truncated human promoter may be susceptible to this conformational change. In fact, it is possible that the truncated human Harvey ras promoter is even more susceptible to this conformational change than is the endogenous rat Harvey ras promoter. This could provide an explanation for the abundance of carcinomas with activating mutations in the transgene in contrast to the lack of carcinomas with endogenous ras gene activating mutations in the Asamoto and Tsuda studies (Asamoto et al., 2000; Tsuda et al., 2001) .
In summary, NMU-induced mammary carcinoma susceptibility was decreased in transgenic rats overexpressing either wild-type Harvey ras or wild-type Kirsten ras driven by rat Harvey ras gene regulatory elements. The reduction in mammary carcinoma development was not due to a decrease in the susceptibility of the endogenous rat Harvey ras gene to NMU-induced activating mutations. Regulation of Harvey ras gene expression may be an important contributor to the role of ras in carcinogenesis, distinct from the role of activating mutations in the ras genes. The results from this study suggest that wild-type Ras protein over-expression may not be a contributor to breast cancer development and may, in fact, act to prevent the development of mammary carcinomas.
Materials and methods
Transgene construction and transgenic rat production
The plasmid NMU-H-ras, containing approximately 6900 bp of the rat Harvey ras gene in pBR322 (Sukumar et al., 1983) was used as the backbone for construction of the HrHr and HrKr transgenes. The coding region of the rat Harvey ras gene was PCR cloned using primers¯anking the ras coding regions from a l-ZAP-II Sprague-Dawley rat brain cDNA library (Stratagene, La Jolla, CA, USA) using the TA cloning kit (In Vitrogen, Carlsbad, CA, USA). The Harvey and Kirsten ras cDNA were introduced into pNMU-H-ras as a Sac I-Dra III cDNA fragment, replacing the mutant Harvey ras coding region and associated intervening sequences, producing plasmids containing the HrHr and HrKr transgene regions, respectively. The promoter region of the HrHr transgene was obtained from a plasmid containing 3800 bp of the rat Harvey ras gene upstream of the coding region, including the ®rst untranslated exon and ®rst intron (Chakraborty et al., 1991) . All subcloning methods used were standard procedures (Sambrook et al., 1989) .
The HrHr and HrKr transgene DNA puri®cations were performed by cutting the transgene region from the pBR322 backbone using restriction digestion with EcoRI and BamHI. The HrHr and HrKr transgene DNA bands were independently resolved on a 0.8% SeaKem (FMC, Rockland, ME, USA) agarose gel and removed from the gel by electroelution. The electroeluted fragment was ethanol precipitated, resuspended in TE buer, and extracted with phenol and chloroform using standard DNA extraction procedures (Sambrook et al., 1989 ). The transgene DNA was then further puri®ed using an Elutip D column (Schleicher and Schuell Inc., Keene, NH, USA) and resuspended in TE buer. The transgene preparation was then dialyzed against TE buer on a type VM 0.05 mm ®lter (Millipore, Bedford, MA, USA). The ®nal HrHr and HrKr transgene DNA concentrations were determined by comparison to the band intensity of known markers (i.e., l-HindIII digested DNA) on an ethidium bromide stained 1% agarose gel and subsequently provided to the U.W. Biotechnology Center Transgenic Animal Facility for use in embryo injections to produce HrHr and HrKr transgenic rats derived from SpragueDawley rats (Harlan-Sprague-Dawley, Madison, WI, USA).
Transgenic rat screening and line development
A PCR-based method was used to screen for transgenic animals. Genomic DNA was isolated from a 0.5 cm segment of tail. The 5' primer used was located in the ®rst intron and a 3' primer was located in the third exon of the Harvey ras or Kirsten ras gene. PCR was performed using AmpliTaq DNA Polymerase (Perkin-Elmer, Foster City, CA, USA) according to product instructions. PCR product from the endogenous Harvey ras gene was 190 bp larger than that from the transgene due to the presence of the second intron in the endogenous gene. Products were resolved on an ethidium bromide stained 1% agarose gel.
Positive transgenic male rats were mated with nontransgenic female Sprague-Dawley rats to produce litters of heterozygous transgenic animals and non-transgenic littermates suitable for carcinogenesis studies. Once transgenic lines were established, records were maintained on all litters documenting parents, date of birth, gender, transgene status, date and cause of death, and tumor pathology.
Transgene copy number determination
The copy number of the HrHr transgene in the R8 line was determined using standard methods for Southern analysis (Sambrook et al., 1989) . Transgene copy number from subsequent lines was determined using a PCR-based method. The ras genes were PCR ampli®ed using a¯uorescein-labeled 5' primer located in the ®rst intron and a 3' primer located in the second exon of the Harvey ras gene, spanning the diagnostic ApaL I site present in the HrHr transgene. PCR product was digested overnight with the ApaL I restriction enzyme allowing distinction between the transgene and the endogenous Harvey ras gene. PCR products were resolved on a 1% SeaKem (FMC) agarose gel and imaged using a FluorImager (Molecular Dynamics, Piscataway, NJ, USA). The transgene copy number was determined by comparing the band intensity of the PCR product of the HrHr transgene to the PCR product band intensity of the endogenous Harvey ras genes after normalizing to the band intensity for the R8 transgenic rat line. Band intensities were quanti®ed using ImageQuant software (Molecular Dynamics).
NMU-induced carcinogenesis studies in transgenic rat lines
Transgenic males were bred with non-transgenic female Sprague-Dawley rats to acquire litters with females containing transgenic and non-transgenic littermates. Fifty mg/kg NMU (Ash Stevens Inc., Detroit, MI, USA) in acidi®ed saline was administered by tail vein injection to 42-to 50-day-old transgenic and non-transgenic female littermates. For all HrHr and HrKr transgenic lines, carcinogenesis studies included untreated transgenic rats and non-transgenic littermates to determine the background eects of the transgene. Mammary tumor development was recorded weekly starting at 4 weeks after NMU exposure. During the course of the study, tumors ranging in size from 10 to 20 mm were resected. Tumors were sectioned for histological analysis (i.e., hematoxylin and eosin staining) to distinguish carcinomas from non-carcinomas. Sections from each tumor were also stored at 7808C for molecular analysis. Eighteen weeks after NMU exposure, animals were necropsied and mammary tumors were prepared for histopathological and molecular analyses, as described above.
Endogenous Harvey ras and transgenic ras mutation analysis NMU-induced mammary tumors were screened for G35 to A35 mutations in the endogenous rat Harvey ras genes using a PCR-based designed diagnostic RFLP method developed by Kumar and Dunn (1989) . DNA was extracted from mammary tumors and used as a template for PCR ampli®cation. Mammary tumors either with or without established G35 to A35 mutations in the Harvey ras gene were used as positive and negative controls, respectively.
Ampli®cation of the multiple copies of the transgene dilutes the presence of a single activated transgene below the limits of detection using allele-speci®c oligonucleotide hybridization. Screening for mutations in the HrHr or HrKr transgene required an initial step that selectively enhanced the relative percentage of G35 to A35 activated transgene PCR product. First, the transgene was ampli®ed using a 5' primer that created a BstN I restriction site in the wild-type gene PCR product and a 3' primer that spanned the junction of the second and third exons so that the transgene was selectively ampli®ed, without ampli®cation of the endogenous Harvey ras gene. The PCR-product was digested overnight with BstN I to reduce the relative levels of the wild-type gene ampli®cation product. The digested PCR product was subsequently PCR ampli®ed using a 5' primer that creates an Hph I restriction site in a PCR product containing the G35 to A35 mutation. PCR product containing the endogenous gene was selectively ampli®ed using a 3' primer present in the second intron of the Harvey ras or Kirsten ras gene that is not present in the pseudogene or transgenes. The PCR products were restriction digested with Hph I and resolved on a 1% agarose gel stained with ethidium bromide. G35 to A35 mutations in the transgene were identi®ed by the presence of an 86 bp band resulting from the Hph I restriction digest.
Statistical analysis
The eect of transgene on 18-week tumor multiplicity was assessed for the HrHr and HrKr transgenic lines using a generalized linear model assuming Poisson distributed counts.
Oncogene Decreased mammary carcinogenesis in ras transgenic rats TA Thompson et al For analyses where lines were pooled, terms were included to account for the eect of line.
